Your browser doesn't support javascript.
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.
Sweeney, Daniel A; Tuyishimire, Bonifride; Ahuja, Neera; Beigel, John H; Beresnev, Tatiana; Cantos, Valeria D; Castro, Jose G; Cohen, Stuart H; Cross, Kaitlyn; Dodd, Lori E; Erdmann, Nathan; Fung, Monica; Ghazaryan, Varduhi; George, Sarah L; Grimes, Kevin A; Hynes, Noreen A; Julian, Kathleen G; Kandiah, Sheetal; Kim, Hannah Jang; Levine, Corri B; Lindholm, David A; Lye, David C; Maves, Ryan C; Oh, Myoung-Don; Paules, Catharine; Rapaka, Rekha R; Short, Willam R; Tomashek, Kay M; Wolfe, Cameron R; Kalil, Andre C.
  • Sweeney DA; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Tuyishimire B; The Emmes Company, LLC, Rockville, MD, USA.
  • Ahuja N; Department of Medicine, Stanford University, Palo Alto, CA, USA.
  • Beigel JH; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Beresnev T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Cantos VD; Department of Medicine, Emory University, Atlanta, GA, USA.
  • Castro JG; Department of Medicine, University of Miami, Miami, FL, USA.
  • Cohen SH; Department of Internal Medicine, University of California Davis, Sacramento, CA, USA.
  • Cross K; The Emmes Company, LLC, Rockville, MD, USA.
  • Dodd LE; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Erdmann N; Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
  • Fung M; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Ghazaryan V; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • George SL; Department of Medicine, Saint Louis University and St. Louis VA Medical Center, Saint Louis, MO, USA.
  • Grimes KA; Department of Medicine, Houston Methodist, Houston, TX, USA.
  • Hynes NA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Julian KG; Department of Medicine, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
  • Kandiah S; Department of Medicine, Emory University, Atlanta, GA, USA.
  • Kim HJ; Community Health Systems Department, University of California San Francisco, San Francisco, CA, USA.
  • Levine CB; Department of Nursing, Kaiser Permanente National Patient Care Services, Oakland, CA, USA.
  • Lindholm DA; Department of Internal Medicine Galveston, University of Texas Medical Branch, TX, USA.
  • Lye DC; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Maves RC; Department of Medicine, Brooke Army Medical Center, Joint Base San Antonio-Ft Sam Houston, TX, USA.
  • Oh MD; National Centre for Infectious Diseases, Singapore, Singapore.
  • Paules C; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
  • Rapaka RR; Lee Kong Chian School of Medicine, Singapore, Singapore.
  • Short WR; Yong Loo Lin School of Medicine, Singapore, Singapore.
  • Tomashek KM; Departments of Internal Medicine and Anesthesiology, Wake Forest University, Winston-Salem, NC, USA.
  • Wolfe CR; Department of Internal Medicine, Seoul National University Hospital College of Medicine, Seoul, Korea.
  • Kalil AC; Department of Medicine, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Open Forum Infect Dis ; 10(5): ofad205, 2023 May.
Article in English | MEDLINE | ID: covidwho-2326544
ABSTRACT
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Language: English Journal: Open Forum Infect Dis Year: 2023 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Language: English Journal: Open Forum Infect Dis Year: 2023 Document Type: Article Affiliation country: Ofid